The new unit marks a milestone in advancing first in-human, early phase trials, supporting cancer therapies and preparing for ...
As the cell and gene therapy (CGT) pipeline continues to expand, the industry faces a critical bottleneck: limited, CGT-experienced site capacity. Traditional sites are oversubscribed, while qualified ...